ESG-206

N/A

Report date: 2026/03/11 20:02:12

Base Information

Drug NameESG-206
Drug Alias NameESG-206
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionB-cell activating factor receptor modulators
TargetsB-cell activating factor receptor
Therapy Area/IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicSjogren's Syndrome +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Escugen Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Escugen Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicSjogren's Syndrome +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A